PhD presentations from Ms Katherine Ognenovska & Ms Vennila Mathivanan

Event date: 
Tuesday, 23 February 2021 - 1:00pm to 2:00pm

Webinar via Microsoft Teams Live Event
Please click on the link just before the start of the webinar

Contact for inquiries: 
Rata Joseph, +61 (2) 9385 0900 or
Booking deadline: 


Kirby Institute Seminar Series presents

Ms Katherine Ognenovska  

Ms Katherine Ognenovska
Research Assistant, Immunovirology and Pathogenesis Program, Kirby Institute

Katherine Ognenovska is a PhD student with the Kirby Institute’s Immunovirology and Pathogenesis Program. Her thesis explores the fundamental mechanisms of epigenetic silencing, with the hope of applying them to future gene therapeutics.


Ms Vennila Mathivanan  

Ms Vennila Mathivanan
Research Assistant, Immunovirology and Pathogenesis Program, Kirby Institute

Vennila Mathivanan is a PhD student with the Kirby Institute's Immunovirology and Pathogenesis Program. She recently submitted her PhD thesis, which focused on lentiviral gene delivery into resting T-cells. Her research interests include lentiviral vectors and lentiviral gene therapy, as well as HIV envelope glycoproteins and their CD4 independence.



Elucidating the Mechanisms of RNA-Induced Transcriptional Silencing Machinery in a HIV-1 Therapeutic
Ms Katherine Ognenovska
Epigenetic silencing is an evolutionarily conserved process that can be induced by synthetic RNA. It offers potent and targeted suppression of HIV-1. However, the mechanisms underlying human epigenetic silencing are poorly understood. To harness the pathway to its full potential, and help develop a powerful HIV-1 therapeutic, we set out to identify the silencing machinery.

Lentiviral System for Gene Delivery into Resting T-cells
Ms Vennila Mathivanan
Current gene delivery systems suffer from poor genetic delivery into resting T-cells and requires multiple viral challenges, activation and expansion of cells ex vivo. However, this leads to lower engraftment, proliferative potential and potency. Vennila will present her findings towards a viable platform to build towards the generation of resting T-cell product for use in vivo. 

Opinions expressed in the Kirby Institute Seminar Series are solely those of the speaker and do not necessarily represent the views or opinions of the Kirby Institute or UNSW.